RS-1805 is under clinical development by Reistone Biopharma and currently in Phase I for Crohn’s Disease (Regional Enteritis). According to GlobalData, Phase I drugs for Crohn’s Disease (Regional Enteritis) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how RS-1805’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

RS-1805 overview

RS-1805 is under development for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease. It is administered by oral route. The drug candidate acts by targeting nuclear receptor retinoic acid receptor-related orphan receptor gamma (RORgamma).

Reistone Biopharma overview

Reistone Biopharma is a clinical stage biopharmaceutical company that focused on developing novel medicines for life threatening autoimmune diseases. The company is headquartered in China.

For a complete picture of RS-1805’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.